How AstraZeneca Is Playing Its Cancer Cards To Become An $80 ... Japan, the U.K. and the U.S. each year, Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit, ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

We expect AstraZeneca AZN to beat expectations when it reports second-quarter 2023 results on Jul 28. In the last reported quarter, the company delivered an earnings surprise of 11.63%.

AstraZeneca's New-York listed ADR rose 2.6% shortly after the open; shares in the drugmaker sold off Monday after it reported mixed results in a trial for an experimental cancer drug.

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory ...

Tangent. AstraZeneca reported $33.7 billion in total revenue through the third quarter and raised its guidance for total revenue this year from a low-to-mid single-digit percentage increase to a ...

Attempts by Oxford University researchers and AstraZeneca Plc to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans ...

The FTSE 100 closed down 7.75 points at 8416.45. Among firms with updates today are AstraZeneca, Kingfisher, SSP Group, Pennon, CVS Group and Naked Wines.

We expect AstraZeneca AZN to beat expectations when it reports first-quarter 2023 results on Apr 27. In the last reported quarter, the company delivered an earnings surprise of 1.47%.